The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BROKER RATINGS SUMMARY: Shore Says Buy Shire, Hold GlaxoSmithKline

Wed, 25th May 2016 08:34

LONDON (Alliance News) - The following shares received analyst recommendations Wednesday morning and Tuesday:
----------
FTSE 100
----------
GOLDMAN RAISES COMPASS GROUP TO 'NEUTRAL' ('SELL') - TARGET 1269 (1020) PENCE
----------
EXANE BNP RAISES SEVERN TRENT TARGET TO 2050 (1900) PENCE - 'UNDERPERFORM'
----------
DEUTSCHE BANK RAISES VODAFONE PRICE TARGET TO 300 (295) PENCE - 'BUY'
----------
Investec Cuts Barclays To Hold From Buy, Keeps Target At 195p
----------
MACQUARIE RAISES SCHRODERS PRICE TARGET TO 2400 (2300) PENCE - 'NEUTRAL'
----------
UBS CUTS CAPITA GROUP PRICE TARGET TO 1125 (1200) PENCE - 'NEUTRAL'
----------
BARCLAYS RAISES RIO TINTO PRICE TARGET TO 2600 (2300) PENCE - 'OVERWEIGHT'
----------
SHORE CAPITAL INITIATES GLAXOSMITHKLINE WITH 'HOLD' - TARGET 1500 PENCE
----------
SHORE CAPITAL INITIATES SHIRE WITH 'BUY' - TARGET 5600 PENCE
----------
MACQUARIE CUTS BT GROUP PRICE TARGET TO 360 (375) PENCE - 'UNDERPERFORM'
----------
FTSE 250
----------
JPMORGAN CUTS ENTERTAINMENT ONE PRICE TARGET TO 214 (217) PENCE - 'OVERWEIGHT'
----------
JPMORGAN RAISES HOMESERVE PRICE TARGET TO 426 (415) PENCE - 'NEUTRAL'
----------
Liberum Lifts Homeserve Target To 550p From 500p, Keeps Buy
----------
JEFFERIES RAISES BIG YELLOW GROUP PRICE TARGET TO 825 (725) PENCE - 'HOLD'
----------
JPMORGAN CUTS STAGECOACH TO 'NEUTRAL' ('OVERWEIGHT') - TARGET 256 (338) PENCE
----------
JPMORGAN RAISES NATIONAL EXPRESS TO OVERWEIGHT (NEUTRAL) - TARGET 362 (335) P.
----------
MACQUARIE RAISES JUPITER FUND PRICE TARGET TO 400 (380) PENCE - 'NEUTRAL'
----------
HSBC RAISES MITCHELLS & BUTLERS TO 'BUY' ('HOLD') - TARGET 340 (300) PENCE
----------
HSBC RAISES HALFORDS GROUP PRICE TARGET TO 490 (470) PENCE - 'BUY'
----------
Liberum Ups AVEVA Group Target To 1,500p From 1,450p, Keeps Hold
----------
BARCLAYS CUTS AVEVA GROUP PRICE TARGET TO 1450 (1530) PENCE - 'EQUAL WEIGHT'
----------
GOLDMAN RAISES AVEVA GROUP PRICE TARGET TO 1350 (1300) PENCE - 'SELL'
----------
BARCLAYS CUTS SHAWBROOK PRICE TARGET TO 340 (375) PENCE - 'OVERWEIGHT'
----------
GOLDMAN CUTS UBM PRICE TARGET TO 667 (695) PENCE - 'BUY'
----------
GOLDMAN CUTS DAIRY CREST GROUP PRICE TARGET TO 545 (550) PENCE - 'SELL'
----------
SHORE CAPITAL RAISES RATHBONE BROS TO 'BUY' ('HOLD') - TARGET 1940 PENCE
----------
MAIN MARKET AND AIM
----------
JPMORGAN RAISES DE LA RUE PRICE TARGET TO 530 (500) PENCE - 'NEUTRAL'
----------
BERENBERG RAISES SCAPA GROUP PRICE TARGET TO 310 (300) PENCE - 'BUY'
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.